Common dementia drug found to improve Parkinson’s symptoms

 

Bristol, UK (January 12, 2016) – Scientists have discovered that a commonly prescribed dementia drug could hold the key to helping prevent debilitating falls for people with Parkinson’s. The research, published today in The Lancet Neurology (1), shows people with Parkinson’s who were given the oral drug rivastigmine were 45% less likely to fall and were considerably steadier when walking, compared to those on the placebo.


Parkinson’s affects 127,000 people in the UK and approximately seven million worldwide. 70% of people with Parkinson’s will fall at least once a year, with over a third experiencing falls repeatedly, resulting in fractures, broken bones and hospital admissions (2).


 

Parkinson’s UK Research Fellow Dr Emily Henderson and principal researcher on the study, based at the University of Bristol, said:

 

"With the degeneration of dopamine producing nerve cells, people with Parkinson’s often have issues with unsteadiness when walking. As part of the condition, they also have lower levels of acetylcholine, a chemical which helps us to concentrate – making it extremely difficult to pay attention to walking.

 

"We already know that rivastigmine works to treat dementia by preventing the breakdown of acetylcholine, however our study shows for the first time that it can also improve regularity of walking, speed, and balance. This is a real breakthrough in reducing the risk of falls for people with Parkinson’s."

 

Dr Henderson and her team at the University of Bristol studied 130 people with Parkinson’s who had fallen in the past year. Half the group were given rivastigmine capsules and the other half a placebo for an eight month period.

 

Dr Arthur Roach, Director of Research at Parkinson’s UK, which funded the study said:

 

"People affected by Parkinson’s, their carers, and health and social care professionals have said that preventing falls and improving balance is the biggest unmet need for people living with the condition, other than finding a cure.

 

"Things that may be simple to us, such as walking upstairs or getting up in the middle of the night to get a glass of water, or go to the toilet, are much harder and more dangerous when you could easily fall. You risk breaking bones and then needing an emergency hospital admission.

 

"This trial shows that there may be drugs already available, being used for other purposes, that can be tested to help treat Parkinson’s. This takes us a step closer to improving the quality of life and finding better treatments for people with Parkinson’s."

 

Caroline Maxwell from Northamptonshire, a participant on the study, who was diagnosed with Parkinson’s 13 years ago said:

 

"A few years ago, I had a bad fall while carrying my sewing machine across the room, leaving me in hospital for a week and really denting my confidence.

 

"I’m at the stage where I would walk much better with a replacement joint, but because I fall so frequently my surgeon is reluctant to operate. Falling on my replacement hip would put in an even worse situation than what I’m in now.

 

"By potentially finding a treatment that helps to prevent falls, I’d be able to get a replacement hip and have the confidence to go shopping on my own, without having to constantly rely on the goodness of strangers to pick me up when I fell."

 

 

 

For more information on Parkinson’s UK research, and to donate, visit parkinsons.org.uk/Research.

 

 

Notes to editors 

  1. Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Henderson E J et al. Lancet Neurology. January 2016. http://dx.doi.org/10.1016/S1474-4422(15)00389-0.  
  2. Recurrent Falls in Parkinson ’s disease: A Systematic Review. Allen N E et al. Parkinson’s Disease. 2013
  3. Priority setting partnership to identify the top 10 research priorities for the management of Parkinson’s disease. Deane, K H O et al. BMJ Open. December 2014. doi:10.1136/bmjopen-2014-006434
  4. Dr Emily Henderson, Dr Arthur Roach and Caroline Maxwell are available for interview on request

 

Parkinson’s UK

 

  • Every hour, someone in the UK is told they have Parkinson’s.
  • It affects 127,000 people in the UK – which is around one in 500 of the population.
  • Parkinson’s is a degenerative neurological condition, for which there currently is no cure. The main symptoms of the condition are tremor, slowness of movement and rigidity.
  • Parkinson’s UK is the UK’s leading charity supporting those with the condition. Its mission is to find a cure and improve life for everyone affected by Parkinson’s through cutting edge research, information, support and campaigning.
  • For advice, information and support, visit http://www.parkinsons.org.uk or call our free, confidential helpline on 0808 800 0303.

 

 

University of Bristol – School of Social and Community Medicine

 

More information about the University of Bristol’s School of Social and Community Medicine can be found at http://www.bristol.ac.uk/social-community-medicine/

 

 


University of Bristol, 12.01.2016 (tB).

MEDICAL NEWS

Fitness watches generate useful information, but increase patient anxiety
A new device provides added protection against COVID-19 during endoscopic…
81 million Americans lacking space or bathrooms to follow COVID…
Front-line physicians stressed and anxious at work and home
EULAR: High-Dose Glucocorticoids and IL-6 Receptor inhibition can reduce COVID-19…

SCHMERZ PAINCARE

Wie ein Schmerz den anderen unterdrückt
Opioidtherapien im palliativen Praxisalltag: Retardierte Analgetika zeigen Vorteile
Krankenhäuser und Praxen müssen sich bei der Schmerztherapie nach Operationen…
Morbus Fabry mittels Datenanalysen aus dem PraxisRegister Schmerz aufspüren
Neandertaler besaßen niedrigere Schmerzschwelle

DIABETES

„Körperstolz“: Michael Krauser managt seinen Diabetes digital
Der richtige Sensor – von Anfang an
Diabetes mellitus: Ein Risikofaktor für frühe Darmkrebserkrankungen
Fastenmonat Ramadan: Alte und neue Herausforderung für chronisch Erkrankte während…
Sanofi setzt sich für die Bedürfnisse von Menschen mit Diabetes…

ERNÄHRUNG

Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren
Gesundheitliche Auswirkungen des Salzkonsums bleiben unklar: Weder der Nutzen noch…
Fast Food, Bio-Lebensmittel, Energydrinks: neue Daten zum Ernährungsverhalten in Deutschland
Neue Daten zur Ernährungssituation in deutschen Krankenhäusern und Pflegeheimen: Mangelernährung…
Baxter: Parenterale Ernährung von Patienten mit hohem Aminosäurenbedarf

ONKOLOGIE

Bestmögliche Versorgungssicherheit bei der Krebstherapie mit CAR-T-Zellen
Darolutamid bei Prostatakarzinom: Hinweis auf beträchtlichen Zusatznutzen
Multiples Myelom: Wissenschaftler überprüfen den Stellenwert der Blutstammzelltransplantation
Neues zur onkologischen Supportiv- und Misteltherapie und aktuelle Kongress-Highlights zum…
Neue Darreichungsform zur Antiemese bei Chemotherapie: Akynzeo® ist ab sofort…

MULTIPLE SKLEROSE

Multiple Sklerose: Novartis’ Siponimod verzögert Krankheitsprogression und Hirnatrophie bei aktiver…
Neurofilamente als Diagnose- und Prognosemarker für Multiple Sklerose
Bedeutung der Langzeittherapie bei Multipler Sklerose – mehr Sicherheit und…
Bristol Myers Squibb erhält Zulassung der Europäischen Kommission für Ozanimod…
Einige MS-Medikamente könnten vor SARS-CoV-2/COVID-19 schützen

PARKINSON

Neue Studie zur tiefen Hirnstimulation bei Parkinson-Erkrankung als Meilenstein der…
Putzfimmel im Gehirn
Parkinson-Patienten in der Coronakrise: Versorgungssituation und ein neuer Ratgeber
Neuer Test: Frühzeitige Differenzialdiagose der Parkinson-Erkrankung
Gegen das Zittern: Parkinson- und essentiellen Tremor mit Ultraschall behandeln…